Insider Selling: Athira Pharma (NASDAQ:LONA) CEO Sells $27,687.72 in Stock

Athira Pharma, Inc. (NASDAQ:LONA) CEO Mark James Litton sold 5,156 shares of Athira Pharma stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a total value of $27,687.72. Following the transaction, the chief executive officer owned 57,926 shares of the company’s stock, valued at approximately $311,062.62. This represents a 8.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Athira Pharma Stock Performance

Athira Pharma stock traded down $0.61 during mid-day trading on Thursday, hitting $5.37. The company had a trading volume of 121,497 shares, compared to its average volume of 52,719. Athira Pharma, Inc. has a 12-month low of $2.20 and a 12-month high of $8.36.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LONA. Wall Street Zen downgraded shares of Athira Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Zacks Research raised Athira Pharma to a “hold” rating in a report on Friday, February 27th. Weiss Ratings initiated coverage on Athira Pharma in a research report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Thursday, February 19th. Finally, Cantor Fitzgerald started coverage on Athira Pharma in a research report on Thursday, February 26th. They set an “overweight” rating on the stock. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.